263 filings
Page 2 of 14
8-K
936qlbi0eevt
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
xq2qt5hxr 3jp82
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
y5xnw74l0alz9l739
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
kk5snhff
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
0qtpwgj yatnu2b
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
0gmxaytlr6f
12 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
ARS
9n6l 6w6b
11 Apr 23
Annual report to shareholders
4:08pm
8-K
6swy6c
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
S-8
xfcuth 023
14 Mar 23
Registration of securities for employees
5:16pm
S-8
cotaa714cbth5fcgt
14 Mar 23
Registration of securities for employees
5:15pm
8-K
llssf 0lqv3
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am
8-K
68iw22wtqv316pz
7 Feb 23
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
4:20pm
8-K
2pj8156fvj7f 5tu68
9 Jan 23
January 2023 Larimar Therapeutics Corporate Presentation
4:03pm
EFFECT
aie1nc4xq1xycc48
22 Nov 22
Notice of effectiveness
12:15am
CORRESP
6gqpfblhjhjezr tte7n
18 Nov 22
Correspondence with SEC
12:00am
UPLOAD
enqvbn929 uo0n8re
16 Nov 22
Letter from SEC
12:00am